| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
AJ91 Stock Overview
DocCheck AG offers marketing, customer relationship management, and e-commerce services for the healthcare sector in Europe.
DocCheck Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €15.95 |
| 52 Week High | €37.40 |
| 52 Week Low | €14.65 |
| Beta | 0.54 |
| 1 Month Change | 1.59% |
| 3 Month Change | -17.78% |
| 1 Year Change | -37.21% |
| 3 Year Change | 87.65% |
| 5 Year Change | 72.79% |
| Change since IPO | -42.38% |
Recent News & Updates
Returns On Capital Are A Standout For DocCheck (ETR:AJ91)
To find a multi-bagger stock, what are the underlying trends we should look for in a business? Firstly, we'll want to...
If You Like EPS Growth Then Check Out DocCheck (ETR:AJ91) Before It's Too Late
It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...
Shareholder Returns
| AJ91 | DE Healthcare Services | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.6% | 0.3% |
| 1Y | -37.2% | -37.6% | -20.0% |
Return vs Industry: AJ91 matched the German Healthcare Services industry which returned -36.3% over the past year.
Return vs Market: AJ91 underperformed the German Market which returned -20.4% over the past year.
Price Volatility
| AJ91 volatility | |
|---|---|
| AJ91 Average Weekly Movement | 4.5% |
| Healthcare Services Industry Average Movement | 5.2% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: AJ91 is not significantly more volatile than the rest of German stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: AJ91's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 372 | Frank Antwerpes | https://www.doccheck.ag |
DocCheck AG offers marketing, customer relationship management, and e-commerce services for the healthcare sector in Europe. The company operates DocCheck portal for exchanging information on the Internet, and online and e-commerce services for healthcare market players. It also develops and implements communication strategies for new and traditional media on healthcare and business-to-business sectors; and promotes healthcare startups through seed funding.
DocCheck Fundamentals Summary
| AJ91 fundamental statistics | |
|---|---|
| Market Cap | €80.29m |
| Earnings (TTM) | €11.40m |
| Revenue (TTM) | €85.92m |
7.0x
P/E Ratio0.9x
P/S RatioIs AJ91 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AJ91 income statement (TTM) | |
|---|---|
| Revenue | €85.92m |
| Cost of Revenue | €61.82m |
| Gross Profit | €24.10m |
| Other Expenses | €12.69m |
| Earnings | €11.40m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.27 |
| Gross Margin | 28.05% |
| Net Profit Margin | 13.27% |
| Debt/Equity Ratio | 0% |
How did AJ91 perform over the long term?
See historical performance and comparisonDividends
6.3%
Current Dividend Yield44%
Payout RatioValuation
Is AJ91 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast
Key Valuation Metric
Which metric is best to use when looking at relative valuation for AJ91?
Other financial metrics that can be useful for relative valuation.
| What is AJ91's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | €80.29m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.7x |
| Enterprise Value/EBITDA | 3.4x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does AJ91's PE Ratio compare to its peers?
| AJ91 PE Ratio vs Peers |
|---|
| Company | PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 27.1x | ||
M3V MeVis Medical Solutions | 10.4x | n/a | €57.9m |
NXU Nexus | 47.2x | 16.0% | €832.4m |
COP CompuGroup Medical SE KGaA | 32.3x | 18.0% | €2.3b |
LIK LIMES Schlosskliniken | 18.6x | n/a | €73.3m |
AJ91 DocCheck | 7x | n/a | €80.3m |
Price-To-Earnings vs Peers: AJ91 is good value based on its Price-To-Earnings Ratio (7x) compared to the peer average (27.1x).
Price to Earnings Ratio vs Industry
How does AJ91's PE Ratio compare vs other companies in the European Healthcare Services Industry?
Price-To-Earnings vs Industry: AJ91 is good value based on its Price-To-Earnings Ratio (7x) compared to the German Healthcare Services industry average (32.9x)
Price to Earnings Ratio vs Fair Ratio
What is AJ91's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 7x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate AJ91's Price-To-Earnings Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of AJ91 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: AJ91 (€15.95) is trading below our estimate of fair value (€24.01)
Significantly Below Fair Value: AJ91 is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Future Growth
How is DocCheck forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score
0/6Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
20.8%
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as DocCheck has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Examine whether DocCheck is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
- DocCheck competitive advantages and company strategy can generally be found in its financial reports archived here.
Past Performance
How has DocCheck performed over the past 5 years?
Past Performance Score
3/6Past Performance Score 3/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
41.2%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AJ91 has a high level of non-cash earnings.
Growing Profit Margin: AJ91's current net profit margins (13.3%) are lower than last year (14.6%).
Past Earnings Growth Analysis
Earnings Trend: AJ91's earnings have grown significantly by 41.2% per year over the past 5 years.
Accelerating Growth: AJ91's earnings growth over the past year (23.9%) is below its 5-year average (41.2% per year).
Earnings vs Industry: AJ91 earnings growth over the past year (23.9%) exceeded the Healthcare Services industry -3.9%.
Return on Equity
High ROE: AJ91's Return on Equity (31%) is considered high.
Discover strong past performing companies
Financial Health
How is DocCheck's financial position?
Financial Health Score
6/6Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage
Financial Position Analysis
Short Term Liabilities: AJ91's short term assets (€36.3M) exceed its short term liabilities (€12.1M).
Long Term Liabilities: AJ91's short term assets (€36.3M) exceed its long term liabilities (€6.5M).
Debt to Equity History and Analysis
Debt Level: AJ91 is debt free.
Reducing Debt: AJ91 has no debt compared to 5 years ago when its debt to equity ratio was 0.2%.
Debt Coverage: AJ91 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: AJ91 has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Dividend
What is DocCheck current dividend yield, its reliability and sustainability?
Dividend Score
5/6Dividend Score 5/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Cash Flow Coverage
6.27%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: AJ91's dividend (6.27%) is higher than the bottom 25% of dividend payers in the German market (1.46%).
High Dividend: AJ91's dividend (6.27%) is in the top 25% of dividend payers in the German market (4.5%)
Stability and Growth of Payments
Stable Dividend: AJ91's dividend payments have been volatile in the past 10 years.
Growing Dividend: AJ91's dividend payments have increased over the past 10 years.
Earnings Payout to Shareholders
Earnings Coverage: With its reasonably low payout ratio (44.1%), AJ91's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonable cash payout ratio (72.8%), AJ91's dividend payments are covered by cash flows.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
3.0yrs
Average management tenure
CEO
Frank Antwerpes
no data
Tenure
€211,410
Compensation
Dr. Frank Nicolas Antwerpes serves as the Chief Executive Officer at DocCheck Guano AG. He served as the Chief Executive Officer of DocCheck Medizinbedarf und Logistik GmbH. Dr. Antwerpes serves as Preside...
CEO Compensation Analysis
Compensation vs Market: Insufficient data to establish whether Frank's total compensation is reasonable compared to companies of similar size in the German market.
Compensation vs Earnings: Frank's compensation has been consistent with company performance over the past year.
Leadership Team
Experienced Management: AJ91's management team is considered experienced (3 years average tenure).
Board Members
Experienced Board: AJ91's board of directors are seasoned and experienced ( 23.6 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
DocCheck AG's employee growth, exchange listings and data sources
Key Information
- Name: DocCheck AG
- Ticker: AJ91
- Exchange: XTRA
- Founded: NaN
- Industry: Health Care Technology
- Sector: Healthcare
- Implied Market Cap: €80.290m
- Shares outstanding: 5.03m
- Website: https://www.doccheck.ag
Number of Employees
Location
- DocCheck AG
- Vogelsanger Str. 66
- Cologne
- North Rhine-Westphalia
- 50823
- Germany
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/08/15 00:00 |
| End of Day Share Price | 2022/08/15 00:00 |
| Earnings | 2021/12/31 |
| Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.